Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arvinas, Inc. - Common Stock
(NQ:
ARVN
)
9.000
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Arvinas, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Arvinas Q2 Earnings Call Highlights
↗
August 04, 2026
Arvinas (NASDAQ:ARVN) said it is concentrating resources on its early-stage oncology and neurology pipeline after reaching several strategic milestones in the first half of 2026, including FDA approval...
Via
MarketBeat
Topics
Earnings
Transcript: Arvinas Q2 2026 Earnings Conference Call
↗
August 04, 2026
Arvinas (NASDAQ:ARVN) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time...
Via
Benzinga
Topics
Earnings
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
↗
June 05, 2026
Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where...
Via
MarketBeat
These Analysts Increase Their Forecasts On Arvinas After Q1 Results
↗
May 13, 2026
Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE) for...
Via
Benzinga
Arvinas (NASDAQ:ARVN) Q1 2026 Results: First-Ever PROTAC Approval Offsets Revenue Miss
↗
May 12, 2026
Via
Chartmill
Arvinas Inc (NASDAQ:ARVN) Stock Plummets After Q4 2025 Earnings and Revenue Miss Estimates
↗
February 24, 2026
Via
Chartmill
Earnings Scheduled For November 5, 2025
↗
November 05, 2025
Via
Benzinga
What 4 Analyst Ratings Have To Say About Arvinas
↗
September 17, 2025
Via
Benzinga
Arvinas Q1 Earnings Call Highlights
↗
May 12, 2026
Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline...
Via
MarketBeat
Topics
Earnings
Arvinas (ARVN) Q4 2025 Earnings Call Transcript
↗
February 24, 2026
Arvinas (ARVN) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff
↗
February 12, 2026
Randy Teel has been appointed as President, CEO, as well as a member of the Company’s Board of Directors, effective immediately.
Via
Stocktwits
Top movers in Tuesday's session
↗
November 18, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via
Chartmill
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach
↗
August 07, 2025
Via
Stocktwits
Earnings Scheduled For August 6, 2025
↗
August 06, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
November 18, 2025
Via
Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
November 18, 2025
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via
Chartmill
Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday
↗
November 18, 2025
Via
Benzinga
What Analysts Are Saying About Arvinas Stock
↗
June 02, 2025
Via
Benzinga
These stocks that are showing activity before the opening bell on Tuesday.
↗
November 18, 2025
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
November 18, 2025
Via
Benzinga
Arvinas Inc (NASDAQ:ARVN) Tops Q3 2025 Earnings Estimates and Provides Pipeline Updates
↗
November 05, 2025
Arvinas (ARVN) beat Q3 2025 earnings estimates, with revenue of $41.9M and a smaller-than-expected loss. The biotech also reported strong pipeline progress and a cash runway into 2028.
Via
Chartmill
Forecasting The Future: 7 Analyst Projections For Arvinas
↗
October 15, 2025
Via
Benzinga
This GE Vernova Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
↗
October 15, 2025
Via
Benzinga
Karooooo Posts Downbeat Earnings, Joins ASP Isotopes And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
October 15, 2025
Via
Benzinga
Arvinas Inc (NASDAQ:ARVN) Reports Q2 2025 Earnings: Revenue Misses but EPS Beats Estimates
↗
August 06, 2025
Arvinas Q2 2025 earnings: Revenue missed estimates at $22.4M, but EPS beat at -$0.84. NDA submitted for vepdegestrant, ARV-102 advances in trials. Shares fell pre-market.
Via
Chartmill
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
↗
June 18, 2025
Via
Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
↗
June 09, 2025
Via
Benzinga
Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval
↗
June 06, 2025
Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients
Via
Benzinga
SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
June 02, 2025
Via
Benzinga
Where Arvinas Stands With Analysts
↗
May 05, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
